ClinicalTrials.gov record
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
ClinicalTrials.gov ID: NCT05269381
Public ClinicalTrials.gov record NCT05269381. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
ClinicalTrials.gov public records Last synced May 10, 2026, 4:10 AM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Study identification
- NCT ID
- NCT05269381
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 132 participants
Conditions and interventions
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Breast Adenocarcinoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage III Gastric Cancer AJCC v8
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage III Merkel Cell Carcinoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Clinical Stage IV Gastric Cancer AJCC v8
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IV Merkel Cell Carcinoma AJCC v8
- Clinical Stage IVA Gastric Cancer AJCC v8
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IVB Gastric Cancer AJCC v8
- Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Locally Advanced Cervical Carcinoma
- Locally Advanced Endometrial Carcinoma
- Locally Advanced Gastric Adenocarcinoma
- Locally Advanced Gastroesophageal Junction Adenocarcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Hepatocellular Carcinoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced Melanoma
- Locally Advanced Merkel Cell Carcinoma
- Locally Advanced Renal Cell Carcinoma
- Locally Advanced Skin Squamous Cell Carcinoma
- Locally Advanced Triple-Negative Breast Carcinoma
- Locally Advanced Unresectable Breast Carcinoma
- Locally Advanced Unresectable Cervical Carcinoma
- Locally Advanced Unresectable Gastric Adenocarcinoma
- Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma
- Locally Advanced Unresectable Renal Cell Carcinoma
- Locally Advanced Urothelial Carcinoma
- Metastatic Cervical Carcinoma
- Metastatic Endometrial Carcinoma
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Hepatocellular Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Merkel Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Skin Squamous Cell Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Metastatic Urothelial Carcinoma
- Skin Squamous Cell Carcinoma
- Stage III Cervical Cancer AJCC v8
- Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Stage IIIA Cervical Cancer AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIA Uterine Corpus Cancer AJCC v8
- Stage IIIB Cervical Cancer AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIB Uterine Corpus Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IIIC Uterine Corpus Cancer AJCC v8
- Stage IIIC1 Uterine Corpus Cancer AJCC v8
- Stage IIIC2 Uterine Corpus Cancer AJCC v8
- Stage IV Cervical Cancer AJCC v8
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVA Uterine Corpus Cancer AJCC v8
- Stage IVB Cervical Cancer AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Stage IVB Uterine Corpus Cancer AJCC v8
- Triple-Negative Breast Carcinoma
- Unresectable Cervical Carcinoma
- Unresectable Endometrial Carcinoma
- Unresectable Gastric Adenocarcinoma
- Unresectable Gastroesophageal Junction Adenocarcinoma
- Unresectable Head and Neck Squamous Cell Carcinoma
- Unresectable Hepatocellular Carcinoma
- Unresectable Lung Non-Small Cell Carcinoma
- Unresectable Malignant Solid Neoplasm
- Unresectable Melanoma
- Unresectable Merkel Cell Carcinoma
- Unresectable Renal Cell Carcinoma
- Unresectable Skin Squamous Cell Carcinoma
- Unresectable Triple-Negative Breast Carcinoma
- Unresectable Urothelial Carcinoma
Interventions
- Biopsy Procedure
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Cyclophosphamide Drug
- Magnetic Resonance Imaging Procedure
- Neoantigen Peptide Vaccine Biological
- Pembrolizumab Biological
- Sargramostim Biological
Procedure · Drug · Biological
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2022
- Primary completion
- Mar 30, 2028
- Completion
- Mar 30, 2028
- Last update posted
- Mar 11, 2026
2022 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05269381, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05269381 live on ClinicalTrials.gov.